MEDTIDE(03880) pricing IPO at HK$28.40-30.60 X

20/06/2025 16:22

(Infocast News) MEDTIDE(03880), a peptide-focused CRDMO worldwide. is expected to start its initial public offering on 20 June 2025. Details of the IPO are as follows:

Shares for offer: 16.80 million H shares

Offer price: HK$28.40-30.60 per share

Net proceeds: HK$411.2 million

(1) approximately 76.4% or HK$314.0 million, will be used to further expand our service capability and capacity by constructing our facilities, which includes Rocklin Site, Qiantang Site and Hangzhou Biopharma Town Site, in the United
States and China;
(2) approximately 4.1% , or HK$16.9 million, will be used for our production capacity expansion in China. In addition to Qiantang Site and Hangzhou
Biopharma Town Site, we plan to construct or acquire a new production facility in China in the next two or three years primarily intended for GLP-1 production;
(3) approximately 9.5% , or HK$39.2 million, will be used to establish sales and after-sales service presence in more regions in Europe to enrich our operations overseas and enlarge our customer pool; and
(4) approximately 10.0% , or HK$41.1 million, will be used for working capital and other general corporate purposes.

Board lot size: 100 shares

IPO entry fee: HK$3090.85

Offer period: 13 June, 2025 to noon on June 25, 2025

Listing date: June 30, 2025

eIPO: www.hkeipo.hk, FINI

(SY)

#IPO

Infocast Limited and its information providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.